Exclusive Summary

• A potential Best-in-Class GLP-1R/GIPR dual peptide agonist, demonstrating superior efficacy in both blood glucose reduction (db/db mice) and weight reduction (DIO mice) compared to the blockbuster drug Tirzepatide in pre-clinical head-to-head studies.
• Distinctly differentiated dosing regimens with a prolonged half-life, supporting the development of once-weekly or even bi-weekly (Q2W) injections, offering a revolutionary upgrade in patient compliance.
• Ultra-high potency requiring only one-third of the Tirzepatide dose (10nmol/kg vs. 30nmol/kg) to achieve anticipated efficacy, translating to enormous advantages in API manufacturing capacity and Cost of Goods Sold (COGS) at commercial scale.
• Biologically de-risked and highly characterized validated mechanism, currently advancing through IND-enabling tox/safety studies, making UB662 an ideal license-out asset for MNCs seeking rapid entry or expansion in the $100B+ metabolic landscape.

Asset Materials

Contact Us for Full Materials